u/PepSmartOfficial

FDA's published-literature review found five small BPC-157 studies involving about 80 exposed people. Two were randomized against placebo, and the only efficacy trial did not separate from placebo. A sponsor-posted gummy record reports completed status and 40 actual participants, while another sponsor record reports a subcutaneous trial; both lack posted results. No country has approved BPC-157, WADA bans it at all times, and it is absent from the current 503A Bulks List.

full writeup - https://pepsmart.net/articles/bpc-157-evidence-map

BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon came off FDA's Category 2 safety-risk list in April 2026. The nominations were withdrawn, so the listings went with them. FDA cleared nothing. One enforcement flag gone.

July 23-24 the Pharmacy Compounding Advisory Committee reviewed all seven for the 503A Bulks List. That's a compounding ingredient question, not drug approval. They recommended six for inclusion, each tied to a specific indication, and voted DSIP down. BPC-157 for ulcerative colitis, KPV and TB-500 for wound healing, MOTS-c for obesity and osteoporosis, Semax for cerebral ischemia and migraine, Epitalon for insomnia.

Every vote was narrow and every one went against FDA's own reviewers, who recommended adding none of them. No written minutes posted yet. The tallies come from the archived webcasts and trade press, and those disagree on at least one day-two count.

Nothing is compoundable today. The list is unchanged. PCAC only advises, and FDA has to run notice-and-comment rulemaking before anything gets added. It can agree, narrow the indication, or sit on it.

2024 is worth looking at. Same committee voted against every peptide-adjacent substance it reviewed. ipamorelin-related, kisspeptin-10, AOD-9604-related, CJC-1295-related, thymosin alpha-1-related at 17 to 4.

WADA didn't move. 2026 list still has BPC-157 under S0 and thymosin beta-4 derivatives, TB-500 included, under S2. if you get tested, nothing changed.

none of this says anything about product quality. a committee vote doesn't test the vial in your fridge.

on GHK-Cu, fda says it intends to bring it to PCAC before the end of february 2027, injectable and non-injectable separately.

Full write-up with the FDA, RAPS, WADA, and PubMed sources: https://pepsmart.net/articles/fda-peptide-compounding-pcac-2026

Semaglutide (Wegovy) resists DPP-4 breakdown and binds albumin. That's why the injection lasts about a week.

Tirzepatide (Zepbound) hits both GIP and GLP-1 receptors. Elimination half-life is around 5 to 6 days.

Setmelanotide (Imcivree) works at MC4 receptors. Approved for specific genetic, syndromic, and acquired hypothalamic obesity indications. The diagnosis and age cutoffs are narrow.

Lutetium Lu 177 dotatate (Lutathera) attaches a receptor-binding cyclic peptide to radioactive lutetium-177. For somatostatin-receptor-positive tumors.

Oral semaglutide uses SNAC to get absorbed in the stomach. absolute oral bioavailability is still about 1 to 2 percent.

Enlicitide (Lipfendra) is a macrocyclic PCSK9-binding peptide formulated with sodium caprate. first FDA-approved oral PCSK9 inhibitor, July 2026. also around 1 percent bioavailability.

retatrutide has published phase 2 and phase 3 studies. FDA has not approved it. FDA also says it hasn't been found safe and effective for any condition, and that federal law bars its use in compounding.

if you're reading a claim about any of these, check the exact molecule, the formulation, the population it was studied in, and where the claim came from. an approved label and a trial paper are different kinds of evidence. a vial someone is selling online isn't either one.

full write-up with sources: https://pepsmart.net/articles/how-peptide-drugs-are-changing-medicine

disclosure: I run pepsmart. not medical advice.

Most GHK-Cu research is topical. That matters because most of what gets sold for recovery is injectable.

The skin studies use topical application, and they're small. Some show measurable improvement in skin appearance (PMID 16847171).

Wound healing data is a mouse model (PMID 28370978). There's one registered mid-stage human trial going right now, a 0.1% topical gel, still recruiting, no results posted (NCT07437586).

Injectable GHK-Cu for tendons or joints has no completed controlled human trial and nothing registered. The recovery case comes from extrapolating topical and animal data.

the hair claims are their own thing. the study people cite for copper peptides growing hair follicles used AHK-Cu, alanyl-histidyl-lysine copper (PMID 17703734). different peptide. a lot of GHK-Cu hair marketing borrows that study without mentioning the swap.

most of the mechanism writeups, including the 4,000 genes number, trace back to the researcher who discovered the compound and later commercialized it. treat it as rationale.

copper. it's about a sixth of the complex by mass. daily requirement is 0.9 mg, oral upper limit is 10 mg. injecting bypasses the gut, which normally regulates how much copper gets absorbed. wilson disease or any copper handling issue, don't.

full evidence map with citations: https://pepsmart.net/articles/ghk-cu-evidence-map

Retatrutide took off about 24% of body weight at the top dose in phase 2, and the phase 3 TRIUMPH readouts are running higher than that. More than any other obesity drug in trials so far. So people want to know how much of it is muscle.

The lean share looks ordinary. About a quarter. Same split you get from plain dieting.

Retatrutide's phase 2 body-comp substudy (the type 2 diabetes one, with DXA scans) reported that its proportion of lean-mass loss was similar to other obesity drugs. The authors read that as reassurance that a bigger share of lean tissue isn't going even though the total loss is larger. In that substudy, 36 weeks, fat mass was down about 23% from baseline at 12 mg. No separate lean number was published, just the share.

For comparison, tirzepatide in SURMOUNT-1 over 72 weeks: fat down about 34%, lean down about 11%, which works out to roughly a quarter of the weight lost being lean. Same as the placebo group. Semaglutide in STEP-1 over 68 weeks: fat down about 19%, lean down about 10%, and lean actually went up about 3 points as a share of body weight.

Two caveats on the numbers themselves. DXA "lean mass" isn't pure muscle. Water, glycogen and organ tissue all land in that bucket. Direct muscle measurement (D3-creatine) reads lower, and it tracks strength and fall risk better, so a scary lean-mass number overstates how much real muscle left. And muscle comes up more with reta because the loss is bigger. a normal quarter share of a very large, fast loss is more kilograms in absolute terms. nothing in the data points to reta doing something specific to muscle tissue.

what has trial evidence behind it is the same regardless of which drug you're on. protein first. there was a controlled 4-week trial in young men, 40% deficit, everyone lifting, and the higher-protein group gained about 1.2 kg of lean mass and lost 4.8 kg of fat while the lower-protein group at the same deficit held lean roughly flat and lost less fat. young guys, four weeks, so don't bank on the exact figures. then resistance training. among dieting older adults, the groups that added resistance work lost about 2 to 3% of lean mass, aerobic-only lost about 5%.

the appetite drop is where people get into trouble. it hits hard, and protein tends to scale down with everything else you're eating less of, so you can slide under what holds muscle in a deficit without noticing it happen. track protein separately from calories.

reta is still investigational. not FDA approved, still in phase 3 as of mid-2026.

full write-up with the sources: https://pepsmart.net/articles/retatrutide-and-muscle-loss

Ozempic and Wegovy are both semaglutide, made by Novo Nordisk, injected once a week under the skin. The molecule is identical. The labels aren't.

Approved use. Ozempic is approved for type 2 diabetes, plus heart and kidney risk reduction in people who already have diabetes. Wegovy is approved for weight management, heart risk reduction in people with existing heart disease, and MASH. The MASH approval is an accelerated one and could get pulled if the confirmatory trial doesn't hold up.

Top dose. Ozempic stops at 2 mg a week. Wegovy goes to 2.4 mg maintenance, and there's a 7.2 mg option now for more weight loss. That higher ceiling is why Wegovy ended up as the weight brand. In STEP-1, 2.4 mg produced about 14.9% body weight loss vs 2.4% on placebo over 68 weeks.

Coverage. Insurers pay by approved use, not by molecule. The same semaglutide can get covered as Ozempic and denied as Wegovy on a plan that pays for diabetes meds but not weight loss meds. That's where the wildly different price quotes come from.

Ozempic will cause weight loss. It's the same drug. It just isn't approved for that, so a weight loss script for it is off label. Wegovy is the version approved and dosed for weight.

Rybelsus is semaglutide too. daily pill, type 2 diabetes, 3 / 7 / 14 mg. not a weight drug. also not the same thing as the newer oral Wegovy, which is a 25 mg daily tablet approved for weight.

labels on this stuff move. both got revised in mid 2026 and semaglutide keeps picking up doses and uses. if you care about a specific dose or indication, pull the current DailyMed label instead of trusting a number from a year ago.

full side by side with sources: https://pepsmart.net/articles/ozempic-vs-wegovy-same-drug

disclosure: i run pepsmart. not medical advice.

BPC-157 is one of the most promising recovery peptides going, and it earns the interest. Here is where it actually stands, pinned to published sources.

The animal data is strong and consistent. In rats it sped up cut Achilles tendon healing, protected the stomach lining against alcohol and NSAIDs, and improved blood flow recovery after a blocked artery. That is a real, repeatable signal, and it lines up with what a lot of people report using it for: tendon and joint injuries, and gut issues. Those user reports are consistent enough to take seriously.

The missing piece is a finished human trial. A 2025 review found three small human pilots and called it investigational. The most quoted result, knee pain relief in 14 of 16 people, had no control group and mixed in some BPC-157 plus TB-500 use, so it points in a good direction without proving it. A proper phase 2 trial in hamstring strains is now recruiting, so the human evidence is catching up to the interest.

A few things that help you get the most out of it:

Oral vs injectable: the capsule makes the most sense for gut issues, where it acts locally. For a tendon or joint, injection is the stronger route. BPC-157 survives stomach acid, over 24 hours in gastric juice, but surviving the stomach is a separate step from getting into the blood. Even engineered oral semaglutide only lands about 0.4 to 1 percent of the dose, and a plain capsule has none of that tech.

The cancer question is the one real open risk. BPC-157 promotes blood vessel growth through VEGFR2, and tumors also need vessels, so in theory a pro-angiogenic compound could feed one. No human study has tested this either way. With a personal or family cancer history, that unknown deserves real weight.

Dosing is extrapolated from rats. There is no published human half-life, so the common milligram per day protocols are educated guesses.

FDA status in 2026: no approved product. It came off the FDA interim safety concern compounding list, and an FDA advisory committee reviews it for pharmacy compounding on July 23-24 2026, nominated for ulcerative colitis, which fits where the animal gut evidence is strongest. That committee advises, it does not approve.

Sport: banned at all times under WADA, same for the BPC-157 plus TB-500 Wolverine pairing.

Bottom line: a promising peptide with a strong animal signal, a plausible mechanism, and encouraging user reports, with the human trials just now starting. Plenty of reason for genuine interest, with the cancer unknown and the human data gap kept in view.

I run pepSmart. Not medical advice.

Full write-up with every source: https://pepsmart.net/articles/bpc-157-common-questions

NAION is basically a small stroke of the optic nerve. Sudden vision loss in one eye, usually painless, and a lot of people notice it right when they wake up. It's uncommon on its own, around 2 to 10 cases per 100,000 people over 50 per year, and it's usually permanent with no proven treatment.

The 2024 study that kicked off the panic found a 4x to 8x jump. It came from one eye clinic looking at people who were already there for eye problems. Enough to flag a possible link. Doesn't tell you your own odds.

The bigger nationwide studies came in way lower. A Danish study of 424,000 people with type 2 diabetes found about double the risk. A 2026 US study of 480,000+ matched pairs found roughly the same, about double for semaglutide, and the authors said the absolute increase was small.

June 2025 the EU medicines regulator and the WHO both called it a very rare side effect, up to 1 in 10,000, with the extra risk at about one additional case per 10,000 person-years.

so it's real but rare. doubling a rare thing still leaves it rare. not a reason to quit over a headline.

the part worth actually doing. if you get sudden vision loss or blurring in one eye, especially waking up with it, treat it as an emergency and get seen fast. catching it early doesn't reverse it but it gets you a diagnosis, the call on whether to stop, and a check on your other eye. if you've got sleep apnea, high blood pressure, or a crowded optic disc you're already higher risk at baseline, so getting an eye exam on record early isn't a bad idea.

not medical advice, just what the sources say. full write-up with the study links and sources: https://pepsmart.net/articles/ozempic-vision-loss-naion

On the standard 2.4 mg dose the two year trial (STEP 5) put mean weight loss at 15.2 percent against 2.6 percent on placebo, and about a third of people lost 20 percent or more. The plateau everyone worries about is already in the data. Loss flattens around week 60 and then holds. Hitting a wall near month 15 is the normal shape of it, not a sign anything broke.

Stopping brings the weight back and this is the part people don't want to hear. In the STEP 1 extension, a year after stopping, people had regained about two thirds of what they lost, and the average went from 17.3 percent back to 5.6 percent. STEP 4 shows the other side. People who kept dosing lost another 7.9 percent, and the ones moved to placebo regained 6.9 percent. Staying on it is the maintenance plan. If 2.4 is rough there's a lower 1.7 mg dose that's an approved maintenance option, so you're not stuck picking between full dose and quitting.

side effects off the label: nausea around 44 percent, diarrhea 30 percent, vomiting 24 percent, constipation 24 percent. reads bad, but about 98 percent of the gut stuff was mild or moderate, it clusters during the dose increases, and it fades. slowing the ramp helps most, you're allowed to hold a dose an extra four weeks. smaller lower fat meals too. constipation is the one people underrate. hydrate first since you're probably a little dehydrated from eating and drinking less, then fiber, then move around, and a cheap PEG laxative if you need it. don't let it sit for a week.

wegovy isn't the strongest option now either. head to head (SURMOUNT-5) tirzepatide came out ahead, 20.2 percent vs 13.7 percent at 72 weeks. there's also a newer 7.2 mg high dose sitting around 20.7 percent and a 25 mg oral pill. and the cheap compounded route mostly closed, the FDA called the shortage resolved in february 2025, so a compound that's basically a copy isn't allowed anymore.

none of this means don't use it. it works. just go in knowing the plateau is normal, the weight comes back if you stop, and the dose ramp is where the side effects are.

full write up with all the sources is on my site: https://pepsmart.net/articles/wegovy-questions-answered (disclosure, pepsmart is mine)

not medical advice.

In the phase 2a trial (Sanyal et al., Nature Medicine 2024, n=98, people with obesity and fatty liver) liver fat dropped about 81% on 8 mg and about 82% on 12 mg at 24 weeks. Placebo basically didn't move.

Most people on the higher doses got their liver fat back under 5%, which is the normal range. 79% on 8 mg and 86% on 12 mg. Zero on placebo.

The reason it probably hits liver fat harder than semaglutide or tirzepatide is the glucagon arm those two don't have. Glucagon tells the liver to burn fat and make less of it. A fat-burning marker (beta-hydroxybutyrate) went up two to threefold with the dose.

here's the part that keeps getting left out. this was liver fat on an MRI, not a biopsy. the trial did not show that the inflammation and scarring (MASH, fibrosis) got better, and it couldn't. those are the things that actually make fatty liver dangerous.

it was small and hypothesis generating. not enriched for MASH, and it excluded people with advanced scarring. liver enzymes (ALT) didn't really change.

for context the two drugs actually approved for MASH with fibrosis (resmetirom and Wegovy) got there on biopsies from 888 patients showing resolution and fibrosis improvement. retatrutide has the fat number. it does not have the biopsy number yet, and it's still investigational.

so it drains the fat really well but the disease underneath is still unproven. the trials that biopsy the liver are what settle it.

not medical advice.

full writeup on my site:   https://pepsmart.net/articles/retatrutide-and-fatty-liver

Reconstitution is two steps and the second one is easy to misread.

1. Mix the powder with bac water to set a concentration in mg per mL. This part is just division.
2. Draw the volume for your dose and read it on the syringe.

The math:
10 mg vial + 1 mL bac water = 10 mg/mL
a 2 mg dose = 0.2 mL
on a U-100 insulin syringe, 100 units = 1 mL, so 0.2 mL = 20 units

the thing to keep straight is that units are volume, not mg. drawing to the 20 mark is 0.2 mL, not 20 mg. the FDA has flagged some 5x and 10x overdoses tied to reading units as mg or assuming the wrong concentration. worth planning the whole ladder before you mix too. at 10 mg/mL the 12 mg step is 1.2 mL and that won't fit in a 1 mL syringe, so you'd want a different concentration or a bigger syringe.

dosing. the trials started low and stepped up about every 4 weeks, roughly 2 to 4 to 8 to 12 mg. going faster mostly just adds nausea without getting you there sooner. once weekly because the half life is around 6 days.

full write up with a units table and two calculators (reconstitution and mg to units) is here:
https://pepsmart.net/articles/retatrutide-reconstitution-and-dosing

also free calculation tools here

https://pepsmart.net/calculator

if you're also on insulin or a sulfonylurea the dosing conversation is different.

i wrote this on our site so part of this is self promo, tried to make the post useful even if you never click. reta is investigational and this is educational, not medical advice.

One question that comes up fairly often is whether retatrutide can cause hypoglycemia.

Based on the mechanism of the drug and the clinical trial data available so far, the answer is generally no for people using retatrutide alone.

Retatrutide activates the GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP effects stimulate insulin release only when blood glucose is elevated (glucose-dependent), which is one reason this class of medications rarely causes hypoglycemia by itself. The glucagon component also works in the opposite direction by increasing blood glucose.

In Phase 2 obesity studies involving people without diabetes, gastrointestinal side effects and increased heart rate were reported, while hypoglycemia was not a prominent finding. Studies in people with type 2 diabetes also found retatrutide to be effective at lowering A1c with an overall favorable safety profile.

The main exception is if someone is also taking insulin or a sulfonylurea (such as glipizide, glimepiride, or glyburide). Those medications can cause hypoglycemia on their own, so combining them with retatrutide may require dose adjustments under the guidance of the prescribing clinician.

It’s also worth noting that because retatrutide can suppress appetite significantly, eating too little may cause symptoms like weakness or shakiness that can feel similar to low blood sugar. The only way to know for sure is to check a glucose reading.

Retatrutide is still an investigational medication, so this is based on its known mechanism and the published clinical trial data available so far.

I put together a more detailed review with citations to the published studies here if anyone wants to read further:

https://pepsmart.net/articles/retatrutide-and-low-blood-sugar

The room temp window is different for every one of these. straight from the FDA labels:

Ozempic: once it's in use, fine at room temp up to 86F for 56 days. or just keep it in the fridge.

Wegovy: 28 days at room temp.

Mounjaro and Zepbound, the single dose pens or vials: 21 days at room temp then toss it. and with Zepbound, once it's sat at room temp don't move it back to the fridge.

Rybelsus, the tablet: no fridge. keep it in the original bottle somewhere dry.

two things wreck these drugs.

freezing is the big one. every label says don't use it if it froze, even if it looks totally normal after it thaws. the back wall of your fridge and the spot right by the cooling vent can dip below freezing, so keep the pen on a middle shelf.

then heat. a hot car will do it. so will a windowsill in the sun, or a bag that ends up sitting next to a heater. leave it in the original carton and the carton works as a sunshade.

flying. put it in your carry-on. checked bags can freeze in the hold. TSA lets you bring medically necessary liquids over the 3.4oz limit if you declare them at the checkpoint, and gel ice packs are allowed even when they've melted, you just tell the officer. for a single travel day you usually don't need a cooler at all, the room temp window covers a flight plus a layover.

one more. if you're on a compounded vial instead of a branded pen, none of these day counts automatically apply. go by the beyond-use date your pharmacy printed on the vial.

disclosure, i run pepsmart. none of this is medical advice, just what the labels say, check yours.

full writeup with the label sources:
https://pepsmart.net/articles/glp1-storage-out-of-the-fridge

Drugs ending in "gliflozin" are SGLT2 inhibitors. They all work the same way. SGLT2 is a protein in your kidney that reabsorbs most of the glucose you filter out of your blood. These block it, so the extra sugar leaves in your urine instead of going back into circulation.

The five FDA-approved ones, generic to brand:

canagliflozin = Invokana
dapagliflozin = Farxiga
empagliflozin = Jardiance
ertugliflozin = Steglatro
bexagliflozin = Brenzavvy

sotagliflozin (Inpefa) is a close cousin that also blocks SGLT1 in the gut, so it's a dual inhibitor, not a pure SGLT2 one.

As a blood sugar drug the effect is modest. Around 0.5 to 1.0 percent off your A1c, plus a little weight and blood pressure. What made them a big deal was the outcome trials. Dapagliflozin and empagliflozin cut heart failure outcomes regardless of ejection fraction, and the class slows chronic kidney disease even in people without diabetes. That's why a cardiologist or nephrologist might put you on one even if your sugars are fine.

if you take one. genital yeast infections are the common side effect, sugary urine feeds yeast. the rarer serious one is ketoacidosis that can show up at near-normal blood sugar, so it's easy to miss, learn the symptoms. canagliflozin specifically carried a raised amputation signal in its trial, about 5.9 vs 2.8 per 1,000 patient-years, mostly toes and feet.

these aren't a GLP-1. GLP-1s work on appetite and the gut, these work at the kidney. plenty of people are on both.

not medical advice, just what the labels say.

full writeup:  https://pepsmart.net/articles/sglt2-inhibitors-canagliflozin-dapagliflozin

Ozempic babies have two pretty boring explanations and neither one is magic.

First one only applies to tirzepatide, which is Mounjaro and Zepbound. The drug slows down how fast your stomach empties. A birth control pill has to dissolve and absorb in there, so if things are moving slower the pill can get absorbed less completely. The Mounjaro label spells this out. A single 5mg dose dropped the peak level of the pill's estrogen by 59% and total exposure by about 20%.

The label also says the effect is biggest right after your first dose and after every dose increase. So the window where you least expect a problem is the window with the biggest hit. The fix the label gives is to use a backup like condoms or switch to a non-oral method for 4 weeks after you start and 4 weeks after each dose bump.

semaglutide is different. Ozempic and Wegovy actually studied the pill and found no meaningful effect on absorption, and those labels carry no contraceptive warning. so the "any GLP-1 kills your birth control" idea isn't true. it's specific to tirzepatide.

second reason has nothing to do with the pill. losing weight can restart ovulation. if you have PCOS or carry extra weight and your cycles were all over the place, taking weight off can get you ovulating again. this is old fertility advice, it predates these drugs by decades. the drug didn't do anything to your eggs, the weight loss restarted a system that was idling.

and if you do want to get pregnant, these aren't for use in pregnancy. the wegovy label says stop at least 2 months before trying because semaglutide hangs around a long time. so it's not a stop today try tomorrow thing.

none of this is a reason to panic or quit your meds. it's a reason to cover one specific window if pregnancy is a no for you right now.

I have a more in depth writeup on my site, link here https://pepsmart.net/articles/ozempic-babies-why-they-happen

A COA runs two different tests for two different questions. People usually only check one.

HPLC is the purity test. It's the main peak as a percent of the total area the detector saw, usually at 220 nm. It tells you how much of the sample is one dominant thing. It does not tell you that thing is the peptide you ordered. The wrong molecule can post a 99% number all day.

Mass spec is the identity test. It weighs the molecule, and in MS/MS it reads the sequence back. That's the question HPLC can't answer. A 99% pure sample is useless if the molecule is the wrong one.

So a COA with one purity number and no identity test is half a report. you want both on there.

a certificate the seller ran themselves, or paid for and chose to show you, isn't independent verification. even licensed drug makers can't just accept a supplier's cert at face value. the rule (21 CFR 211.84) makes them run their own identity test and keep checking the supplier over time. and you're sitting further down a rougher supply chain than a licensed manufacturer is.

the fakes you can catch without any chemistry:

lot number on the COA has to match the lot on your vial. a test only describes the batch it tested. recycled and doctored COAs both fall apart right here.

no chromatogram or spectrum attached, just a number typed on the page? there's no actual measurement there to look at.

take the report number to the lab that supposedly issued it and ask them to confirm it. a real lab can do that. a made-up cert can't survive the call.

when it really matters, send your own sample to an independent lab yourself. that's the one check nobody in the sale got to rig, because nobody picked the sample but you.

a COA covers one batch on one day. the next batch is its own test. it's a strong signal and nothing more than that.

disclosure: i run a peptide info site, not affiliated with any testing lab. not medical advice.

full writeup:   https://pepsmart.net/articles/how-to-read-a-peptide-coa

Microdosing GLP-1s: you take a small amount of semaglutide or tirzepatide, pay less, get fewer side effects, and still lose the weight. Here's where the actual evidence sits.

The appeal makes sense on paper. Less drug can mean lower cost and milder side effects, and plenty of people want a small maintenance dose after they've already hit their goal.

The problem is nobody has actually tested it. No trial has studied doses below the FDA-approved ones. Whether you still get the benefit at those tiny amounts hasn't been measured, and one university physician put it as basically remaining to be seen.

Worth knowing that starting low isn't some hack people discovered. The approved schedules already start small and ramp up slowly. Semaglutide begins at 0.25 mg and works up to 2.4 mg. Tirzepatide starts at 2.5 mg. A doctor keeping you on a low individualized dose is just normal care, not microdosing.

the thing that actually puts people in the hospital is the source, not the small number. microdosing usually means compounded product you're measuring out yourself, and the FDA has logged hospitalizations from dosing errors and people mixing up mL, mg, and "units."

so the honest split is this. a doctor lowering your dose under supervision is fine. buying compounded product off a website to self-microdose has no evidence it works and a real risk of you screwing up the measurement.

full write-up with the dosing schedules and sources: https://pepsmart.net/articles/glp1-microdosing-what-it-is

Hair loss does show up in the GLP-1 trials but it's uncommon. On Wegovy 3% of adults reported it vs 1% on placebo. On Zepbound it was around 4 to 5% vs 1%.

Women report it way more than men. In the Zepbound trials it was 7.1% in women vs 0.5% in men.

What you're almost certainly dealing with is telogen effluvium. That's the temporary shedding that follows fast weight loss, low protein intake, and physical stress on the body. The Zepbound label ties it to the weight loss itself, not the drug.

The timing is what makes it feel alarming. The shedding usually doesn't start until 2 to 3 months after the change, so by the time you notice it you've been on the med a while and it feels out of nowhere. It then recovers over the months that follow.

it grows back. once your weight and your eating level out the density tends to come back.

stuff that helps: get enough protein, slow the pace down if you have the option, and wait it out. go see a doctor if you get actual bald patches or it keeps going past a few months. they can check your iron and thyroid since those cause shedding too and are easy to rule out.

full write-up with the label figures and sources: https://pepsmart.net/articles/ozempic-hair-loss-why-it-happens. --heads up im the owner of the site

Ozempic face is the gaunt or older look some people get after losing weight on a GLP-1.

The medication isn't doing anything to your face directly. you lose the fat that keeps a face looking full, and the face shows it before the rest of the body catches up.

A 2025 systematic review looked for any sign that GLP-1s strip facial fat on purpose and found none. you get the same effect from bariatric surgery or any other fast weight loss. the term came from a dermatologist in New York around 2023, after a run of patients who felt good about losing the weight but thought they looked older for it.

what's going on under the skin is pretty simple. fat in the cheeks and temples is part of what gives a face its shape, so when it drops fast those areas hollow out. skin that stretched to cover more weight doesn't tighten back at the same speed, so it sags a little. rapid loss also tends to pull down collagen and elastin, which doesn't help.

it shows up most in the middle of the face. cheeks, temples, under the eyes, along the jaw. some people end up looking around five years older than they did before.

if you want to limit it, slower loss helps, somewhere in the range of 1 to 2 lb a week instead of going as fast as possible. enough protein keeps more muscle on you, water helps the skin, and fillers or skin treatments are there if you decide you want them. and if the weight comes back later the face usually fills back in too.

full write-up with the sources: https://pepsmart.net/articles/ozempic-face-what-it-is-and-why-it-happens

for research and educational purposes only. not medical advice.